Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

NCT07162181 · tracked via the Priya Life Science China tracker

Sponsor

Eli Lilly and Company

Phase

Phase 2

Started

2025-08-07

Last updated

2026-04-17

Condition(s) studied

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellB-cell Lymphoma

Investigational drug(s) / intervention(s)

Pirtobrutinib →

Pirtobrutinib: Administered orally.

Study summary

The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Currently enrolled and active in the originator study, JZNJ. A participant is considered active in the study if they are receiving study intervention * Agree to comply with contraception requirements. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies Exclusion Criteria: * Are pregnant, or intend to become pregnant during the study, or within 30 days of last dose of study treatment or to breastfeed during the study or within 1 week of the last dose of study treatment

Primary outcome measure(s)

Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events — Day 1 through 28 days after last dose or start of new anticancer therapy

Trial sites (6)

Facility	City	Region
Beijing Cancer hospital	Beijing	China
Sun Yat-sen University Cancer Center	Guangzhou	China
Harbin Medical University Cancer Hospital	Harbin	China
Shanghai East Hospital	Shanghai	China
Blood Institute of the Chinese Academy of Medical science	Tianjin	China
Union Hospital Tongji Medical College Huazhong University of Science and Technology	Wuhan	China

More Eli Lilly and Company trials in China

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer Active, not recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Active, not recruiting

Other trials for the same condition

A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies Recruiting

Anti CD19 Gene Therapy for B-cell Lymphoma Recruiting

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring Enrolling by invitation

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) Active, not recruiting

Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07162181 on ClinicalTrials.gov ↗ ← All trials in China